This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
The TROP2-directed antibody–drug conjugate datopotamab deruxtecan may be active in patients with advanced or metastatic non–small cell lung cancer, according to preliminary findings. In a phase I trial, the agent elicited responses in almost a quarter of patients and had manageable side effects.
- ©2021 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
This OnlineFirst version was published on February 17, 2021
doi: 10.1158/2159-8290.CD-NB2021-0314
TROP2 ADC Intrigues in NSCLC
Jump to section
Advertisement